AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06258031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin (COMP360)
Description: Up to 10mg on two occasions
Study NCT06014827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06014827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT scan
Study NCT06014827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO
Study NCT06014827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06014827 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo BgRT/SBRT
Study NCT06014827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary study
Study NCT04871750 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein
Description: Daily consumption for 24 weeks
Study NCT04871750 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Casein protein
Description: Daily consumption for 24 weeks
Study NCT05274217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Journey of Transformation-Native Youth Health Leadership Program curriculum
Description: Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.
Study NCT05270993 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Centre-based Cardiac Rehabilitation (CBCR) group
Description: A 4-week centre-based outpatient cardiac rehabilitation programme where patients will receive 12 group-based sessions. Patients will also be given access to online educational resources. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
Study NCT05674357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Evidence-Based Therapy in Cancer (Patients)
Description: The intervention will mirror clinical care in psycho-oncology in which the therapist, collaboratively with their supervisor, will choose specific components of the following evidence-based treatments to administer based on the clinical presentation of the patient and referring problem.~* Cognitive Behavioral Therapy (CBT)~* Acceptance Commitment Therapy (ACT)~* Mindfulness-Based Cognitive Therapy (MBCT)~* Mindfulness-Based Stress Reduction (MBSR)~* Meaning-Centered Psychotherapy (MCP)~* Cognitive Behavioral Therapy for Insomnia (CBT-I)~* CBT for pain~* CBT for fatigue~* CBT for nausea
Study NCT05674357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in Individualized Evidence-Based Therapy in Cancer (Therapists)
Description: Enrolled therapist participants will receive training in evidence-based therapies and deliver therapy to patient participants.
Study NCT05887219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A 4 % Hydroquinone Cream Topically and Oral Tranexamic Acid
Description: Group A was managed with 4% hydroquinone cream as an adjuvant to oral tranexamic acid (250 mg twice daily) for 6 months
Study NCT05887219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B Azelaic Acid 20 % Cream for 6 months
Description: Group B was managed with topical 20% azelaic acid (daily at night) for six months.
Study NCT05230420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clamping
Description: Clamping of chest tube
Study NCT05230420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urine bag
Description: Attachment of a urine bag to chest tube
Study NCT05399732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luspatercept
Description: Patients in each group will be treated for at least 6 months and continue the treatment for an additional 6 months unless disease progress or have intolerable side effects.
Study NCT05399732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Patients in each group will be treated for at least 6 months and continue the treatment for an additional 6 months unless disease progress or have intolerable side effects.
Study NCT06534710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electronic moxibustion apparatus
Description: The experimental group used the electronic moxibustion instrument every day on the basis of the control group
Study NCT05647070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous rectus Fascia TOT
Description: A sterile Foley catheter is placed to drain the bladder, following this, injectable normal saline is utilized using 10 cc syringe for hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through Pfannestiel incision, \~1 cm× \~5 cm rectus fascia strip is isolated from the anterior rectus sheath. Two stay sutures are secured to the corner of the fascial segment on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration
Study NCT06325761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-5007
Description: SY-5007 160 mg, Tablets, 2 discrete single doses separated by 7-days
Study NCT06164327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-908 for Injection
Description: BEBT-908 for Injection,dosage of administration:15mg/m\^2 or 22.5mg/m\^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle,and 21 days as a cycle.
Study NCT06164327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Injection
Description: Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:on the 1st day of each cycle, and 21 days as a cycle.
Study NCT06164327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride for Injection
Description: Gemcitabine Hydrochloride for Injection，dosage of administration:1g/m\^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
Study NCT06164327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin Injection
Description: Oxaliplatin Injection，dosage of administration:100mg/m\^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
Study NCT06164327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Injection
Description: Etoposide Injection,dosage of administration:100mg/m\^2，frequency and duration of administration:on the 1st,2nd and 3rd days of each cycle,and 21 days as a cycle.
Study NCT06164327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide for Injection
Description: Ifosfamide for Injection,dosage of administration:5000mg/m\^2,24 hours of continuous intravenous drip，frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
Study NCT06164327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Injection
Description: Carboplatin Injection，dosage of administration:based on AUC=5, single dose ≤800 mg，frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
Study NCT05824546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention Arm (uSINE-PAMS-technique)
Description: Patients will be lying in a lateral recumbent position and in a fetal position with the neck, back and limbs held in flexion. L3-L4 inter-vertebral space will be identified by palpation of external landmarks of the patients' iliac crests and spinous process of lumbar vertebrae L3, L4 and L5 and confirmed using uSINE-integrated ultrasound. The angle of needle during needle advancement will also be determined using the uSINE-integrated ultrasound. Markings on the patients' skin surface will be made using PAMS (non-sterile component) to enable relocation of the site and angle of the needle entry. Patients' back will be cleaned and draped using aseptic technique. Next, local anaesthesia is infiltrated into the previously identified needle entry site before the LP needle is inserted with location and angulation according to PAMS (sterile component) guidance.
Study NCT04321317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measure of body composition by Air Displacement Plethysmography (ADP)
Description: Each patient included will have one measure of body composition by Air Displacement Plethysmography (ADP) during the initial consultation in the referent center for food disorders of Lyon and one year later.
Study NCT06553911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence-based medical imaging interpretation
Description: In the AI interpretation group, using clinical information, imaging data, and corresponding etiological results of the study participants, an AI diagnostic tool is established to specifically recognize patients' chest medical imaging and construct corresponding diagnostic conclusions.
Study NCT05270993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-CREST group
Description: A 6-week home-based cardiac rehabilitation programme where participants will receive an I-CREST app (to deliver education, medication reminders, exercise and vital monitoring) and a wearable smartwatch device (to track physical activity). Participants will be remotely supervised by the cardiac rehabilitation team via an I-CREST web-portal. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
Study NCT05296161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Personalized B cell tailored ocrelizumab treatment
Study NCT05475808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Static wrist splint treatment
Description: Static wrist splint (volar wrist cock-up orthosis): It extends from the proximal of the metacarpophalangeal (MCP) joint to the distal 2/3 of the forearm, supports the wrist from the volar face. It stabilizes the wrist in 20-30 degrees of dorsiflexion and restricts wrist movements. It allows movement of the MCP joints. Patients will be asked to wear this splint continuously at night and for at least 4 hours during the day for 8 weeks.
Study NCT05475808 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tendon and nerve gliding exercises
Description: Tendon and nerve gliding exercises will be applied 5 sessions a day for 8 weeks. Each session will hold 10 repetitions and approximately 7 seconds in each exercise position.~These exercises involve a sequence of finger movements (for tendon gliding) and wrist and fingers movements (for median nerve gliding).
Study NCT05475808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wrist local steroid injection
Description: Wrist local steroid injection:~After proper area cleaning with povidone solution, 1ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml) steroid injection will be applied around the median nerve with a 22 G injector from ulnar side of the wrist proximal crease under ultrasound guidance.
Study NCT06385951 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Procedure for patients
Description: We will screen patients who undergo an MRI and neuropsychological examination as part of their diagnostic workup. If inclusion and exclusion criteria are met, patients will be asked to undergo additional investigations (FDG-PET, lumbar puncture, tau and amyloid PET and the ALLO iVR task).
Study NCT06385951 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Procedure for healthy controls
Description: Healthy controls will be asked to undergo a neuropsychological examination, the ALLO iVR task, an MRI, FDG-PET and tau-PET.
Study NCT05803850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNC1058 Capsules
Description: HNC1058 Capsules/Placebos, single dose, PO, starting dose of 10 mg escalating up to 80 mg；HNC1058 Capsules/Placebos, 50 mg, single dose, FED.
Study NCT05803850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HNC1058 Capsules
Description: HNC1058 Capsules/Placebos, single dose, PO, starting dose of 10 mg escalating up to 80 mg；HNC1058 Capsules/Placebos, 50 mg, single dose, FED.
Study NCT05552508 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Participants will receive benralizumab subcutaneously.
Study NCT06555757 — intervention group
Intervention type: OTHER
Intervention: Height, weight, and BMI
Description: Height, weight measurement and BMI calculation
Study NCT06555757 — intervention group
Intervention type: OTHER
Intervention: Medical history
Description: Brief medical history including medications/allergies and heart failure related healthcare utilisation over previous 12 months
Study NCT06555757 — intervention group
Intervention type: OTHER
Intervention: Physical examination
Description: Brief physical examination
Study NCT06555757 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood samples
Description: Venous blood samples, to include WCC, HB, CRP and NTproBNP
Study NCT06555757 — intervention group
Intervention type: OTHER
Intervention: Resting vital signs
Description: HR, BP, RR, oxygen saturations on air)
Study NCT06555757 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiogram
Description: LVEF, IVC collapsibility, LV filling pressure, PA pressure
Study NCT06555757 — intervention group
Intervention type: OTHER
Intervention: Sound recordings
Description: Sound recordings (voice/cough/chest) recorded with the in-built microphone in a smartphone
Study NCT06555757 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: Lung ultrasound
Study NCT06555757 — intervention group
Intervention type: OTHER
Intervention: KCCQ questionnaire
Description: Kansas City Cardiomyopathy Questionnaire
Study NCT06555757 — intervention group
Intervention type: OTHER
Intervention: ASCEND-HF score
Description: An in-hospital congestion score which risk stratifies patients admitted with worsening heart failure, developed for the Acute study of clinical effectiveness of Nesiritide in decompensated heart failure trial
Study NCT06555757 — intervention group
Intervention type: OTHER
Intervention: Composite Everest congestion score
Description: A shortened version of the original 18-point score from the EVEREST trial
Study NCT05590741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Therapy via Telehealth
Description: The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
Study NCT06553066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromascular blockage
Description: maintenance of a deep neuromuscular block with rocuronium, titrated to maintain a TOF count of 0, and a PTC between 1-2.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale(Leiden scale : 1 indicates extremely poor conditions, 2 poor conditions, 3 acceptable conditions, 4, good conditions and 5 optimal conditions)
Study NCT06553066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deep neuromascular blockage
Description: maintenance of a deep neuromuscular block with rocuronium, titrated to maintain a TOF count of 0, and a PTC between 1-2.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale(Leiden scale : 1 indicates extremely poor conditions, 2 poor conditions, 3 acceptable conditions, 4, good conditions and 5 optimal conditions)
Study NCT06553066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate neuromascular blockage
Description: maintenance of a moderate neuromuscular block with rocuronium, titrated to maintain a TOF count of 1-2
Study NCT06553066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate neuromascular blockage
Description: maintenance of a moderate neuromuscular block with rocuronium, titrated to maintain a TOF count of 1-2
Study NCT04027569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Specific Functional Scale
Description: A validated patient reported outcome measure that asks patients to write down activities and score them 0 to 10.
Study NCT04027569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS PF
Description: A computer adaptive, validated patient reported outcome measure that measures physical function on a 1 to 100.
Study NCT06555757 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bio impedance and total body water measurement
Description: Bio impedance and total body water measurement using TANITA device
Study NCT04834739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6 minute walk test
Description: The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. 30 m long corridor is used for this test .
Study NCT04834739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1 minute Sit to Stand Test
Description: The 1-minute STS test is performed with a chair of standard height of 46 cm without arm rests. The patient should be ensured to be seated upright on the chair positioned against a wall. The patient sat with the knees and hips flexed to 90°, feet placed flat on the floor hip-width apart, and the hands placed on the hips.The number of repetitions is measured.
Study NCT04834739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fatigue Severity Scale
Description: The Fatigue Severity Scale is a 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders
Study NCT04834739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Research Council (MRC) dyspnea scale
Description: The MRC dyspnea scale is a questionnaire that consists of five statements about perceived breathlessness: grade 1, I only get breathless with strenuous exercise; grade 2, I get short of breath when hurrying on the level or up a slight hill; grade 3, I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking at my own pace on the level; grade 4, I stop for breath after walking 100 yards or after a few minutes on the level; grade 5,  I am too breathless to leave the house.
Study NCT04834739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SF-12
Description: The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
Study NCT05567822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol Hydrochloride
Description: In the esmolol group, patients will receive a bolus dose of esmolol followed by a continuous infusion of esmolol intraoperatively
Study NCT05567822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: In the placebo group, patients will receive a bolus dose of normal saline followed by a continuous infusion of normal saline intraoperatively
Study NCT06032182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRESTR Intervention
Description: 15 1-hour sessions of CRT + SRT
Study NCT06032182 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CRESTR Control
Description: 15 1-hour sessions of SRT alone
Study NCT05700409 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive lifestyle consultations
Description: detailed above
Study NCT05700409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle consultations
Description: detailed above
Study NCT05595109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silymarin
Description: Silymarin administration prevent the neuro-degeneration through inhibiting the activation of microglia, silymarin attenuates the activation of glial cell activation in cellular models possibly through inhibition of inducible nitric oxide synthase (iNOS) production, also reported to protect both microglia and astroglia from oxidative insults induced by peroxide in ex vivo system .~It also significantly reduces doxorubicin-pro-oxidative activity and decreases histological changes in liver and heart tissue . The hepato-protective and cardio-protective effects of silymarin may be attributed to its antioxidant capacity, its ability to prevent lipid peroxidation and its ability to increase glutathione concentration.~silymarin was reported to improve cognitive impairment in mice.